CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted key emerging cancer treatment trends by Big Pharma, including combining immunotherapy with effective chemotherapy regimens, are resulting in significant advancements for the treatment of patients with high unmet medical need types of cancer.  CytRx, along with its wholly owned subsidiary Centurion Biopharma, believe these trends strengthen and enhance the value proposition for their rationally designed albumin binding ultra-high potency anti-cancer agents.

Source: PR Newswire

Pin It on Pinterest